FDA advisers back approval of Bayer's PAH drug riociguat

An FDA advisory panel recommended the approval of Bayer's riociguat as a treatment for two types of pulmonary arterial hypertension. The agency is expected to issue its decision in October. If approved, the drug would be marketed as Adempas.

View Full Article in:

Reuters · Wall Street Journal (tiered subscription model), The

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI
Senior Vice-President Managed Care Mid-Atlantic Region
Mercy Health System
Conshohocken, PA
Associate Chief Financial Officer
Commonwealth Care Alliance
Boston, MA
Assistant General Counsel, Regulatorya
Cardinal Health
Waukegan, IL
Chief Operating Officer
Health Plan of San Joaquin
French Camp , CA